NanoBio Select@ is developing and commercialising products to improve precision diagnostics for chromosomal diseases such as cancer and brain degeneration. They integrate nanoscience, biochemistry and bioengineering into the diagnostic products for early diagnosis, prognosis- and therapy monitoring of diseases. Based on patentable plasmonic nanotechnology, their devices could offer greater sensitivity for biological detection and be more cost-effective.
Xueen Jia and Thomas Wågberg are the project owners of NanoBio Select@ and Xian Li is the project manager.
NanoBio Select@ is currently developing a powerful research tool for new biomarker discovery and drug development. NanoBio Select@ has now recruited a project lab technician (Iqra Nasir) and added a senior engineer (Nicolas Boulanger) to the team for new product development regarding robustness, dynamic range and reproducibility, etc.
– We are happy to present the new team members. Iqra is focusing on technology and product verification. Nicolas, a senior engineer at Umea university physics department, has rich experience in nano fabrication and collaboration with industry. He will help with product development, says Xian Li.
Read more about NanoBio Select@ here.